World's Best Scientists 2026 revealed!
Carsten Bokemeyer

Carsten Bokemeyer

D-Index & Metrics

Medicine

D-Index
132
Citations
70304
World Ranking
2304
National Ranking
113

Overview

Carsten Bokemeyer is affiliated with Universität Hamburg in Germany. Their research activities are primarily focused within the field of Medicine, with significant specialization in areas such as Oncology, Molecular Biology, Hematology, Pulmonary and Respiratory Medicine, and Surgery.

The scientist has contributed extensively to topics including:

  • Colorectal Cancer Treatments and Studies
  • Testicular diseases and treatments
  • Multiple Myeloma Research and Treatments
  • Palliative Care and End-of-Life Issues
  • Cancer survivorship and care
  • Childhood Cancer Survivors' Quality of Life
  • Lung Cancer Treatments and Mutations

Frequent coauthors associated with Carsten Bokemeyer's publications include:

  • Walter Fiedler
  • Katja Weisel
  • Karin Oechsle
  • Gunhild von Amsberg
  • Winfried Alsdorf

Their research has been published in a variety of scientific journals, with a notable record in:

  • Journal of Clinical Oncology
  • Cancers
  • Hämostaseologie
  • Annals of Oncology
  • BMC Palliative Care

Among their recent papers are:

  • "Autopsy Findings and Venous Thromboembolism in Patients With COVID-19," 2020, Annals of Internal Medicine
  • "Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer," 2023, Nature
  • "Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium," 2021, Journal of Clinical Oncology
  • "CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial," 2023, Nature Medicine
  • "Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up," 2022, Annals of Oncology

Best Publications

  • Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

    Jan B. Vermorken;Ricard Mesia;Fernando Rivera;Eva Remenar

  • Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.

    Dominic Wichmann;Jan-Peter Sperhake;Marc Lütgehetmann;Stefan Steurer

  • Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

    Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann

  • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

    Michael Pfreundschuh;Joerg Schubert;Marita Ziepert;Rudolf Schmits

  • The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

    Heinz Ludwig;Simon Van Belle;Peter Barrett-Lee;Gunnar Birgegård

  • Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

    Andreas Engert;Annette Plütschow;Hans Theodor Eich;Andreas Lohri

  • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

    C. Bokemeyer;I. Bondarenko;J. T. Hartmann;F. de Braud

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

    Carsten Bokemeyer;Eric Van Cutsem;Philippe Rougier;Fortunato Ciardiello

  • EAU Guidelines on testicular cancer, 2011 update

    P. Albers;W. Albrecht;F. Algaba;C. Bokemeyer

  • Guidelines on Testicular Cancer: 2015 Update.

    Peter Albers;Walter Albrecht;Ferran Algaba;Carsten Bokemeyer

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

    Marcus M. Schittenhelm;Sharon Shiraga;Sharon Shiraga;Arin Schroeder;Arin Schroeder;Amie S. Corbin

  • The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

    Markus M. Heiss;Pawel Murawa;Piotr Koralewski;Elzbieta Kutarska

  • Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis

    Carsten Bokemeyer;Craig R. Nichols;Jean P. Droz;Hans J. Schmoll

  • Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

    Eric Van Cutsem;Roberto Labianca;György Bodoky;Carlo Barone

  • Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

    Sabine Tejpar;Ilhan Celik;Michael Schlichting;Ute Sartorius

  • Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

    Matthias Schwab;Ulrich M. Zanger;Claudia Marx;Elke Schaeffeler

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

    C. Bokemeyer;M.S. Aapro;A. Courdi;J. Foubert

  • Testicular germ cell tumours

    Ewa Rajpert-De Meyts;Katherine A McGlynn;Keisei Okamoto;Michael A S Jewett

Frequent Co-Authors

Lothar Kanz
Lothar Kanz University of Tübingen
Ronald Simon
Ronald Simon Universität Hamburg
Nicolaus Kröger
Nicolaus Kröger Universität Hamburg
Klaus Pantel
Klaus Pantel Universität Hamburg
Hans-Joachim Schmoll
Hans-Joachim Schmoll Martin Luther University Halle-Wittenberg
Jakob R. Izbicki
Jakob R. Izbicki Universität Hamburg
Boris Fehse
Boris Fehse Universität Hamburg
Markus Graefen
Markus Graefen Universität Hamburg
Heinz Ludwig
Heinz Ludwig University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career opportunities beyond traditional medical school is a smart way to diversify your future in healthcare. Today, a wide variety of accredited online programs provide alternative routes to leadership, advanced practice, and specialized roles within the industry.

Those interested in healthcare administration may consider cheap mha programs to develop essential management and leadership skills while maintaining affordability. For nurses seeking advancement, the best online dnp programs can prepare you for top clinical or research positions.

Aspiring pharmacists have access to pharmacy school online accredited options, making it easier to earn a PharmD with flexible, remote study. In addition, those looking to work in health data and records management can benefit from online rhia certification programs online, which open doors to technology-driven careers in healthcare systems.

Directing your education towards these alternative paths can expand your professional options and create a rewarding, in-demand career within the broader healthcare sector.

Best Scientists Citing Carsten Bokemeyer

Trending Scientists